title: Clinicopathologic significance of histologic grade, pgp, and p53 expression in canine lymphoma.
abstract: To characterize the expression of P-glycoprotein (Pgp) and p53 in different histologic grades of canine multicentric lymphosarcoma (LSA), 31 cases of LSA without prior treatment were studied. The expression levels of the Pgp and p53 proteins were evaluated for their clinicopathologic significance among standard histologic evaluation. Immunohistochemistry (IHC) was performed on formalin-fixed, paraffin-embedded archival samples of 31 previously untreated LSA cases to detect the expression of Pgp and p53. All dogs were subsequently treated with a combination chemotherapy protocol. Remission and survival durations were evaluated for correlation with histologic grade and presence of drug resistance markers. Of the 31 cases, 24 (80%) and 7 (22%) were positive for Pgp and p53, respectively. Overall, the median survival and duration of remission in the study was 246 days and 137 days, respectively. The National Cancer Institute working formulation histologic grade was not associated with either survival or duration of first remission (DOR). The Pgp protein expression and DOR and survival was not statistically significant. Expression of p53 was statistically correlated with survival.
authors.affiliation: Center for Comparative Oncology, Michigan State University, East Lansing, MI, USA. ravidvm@sbcglobal.net
authors.forename: Ravinder S
authors.initials: RS
authors.lastname: Dhaliwal
authors.forename: Barbara E
authors.initials: BE
authors.lastname: Kitchell
authors.forename: Ej
authors.initials: E
authors.lastname: Ehrhart
authors.forename: Victor E
authors.initials: VE
authors.lastname: Valli
authors.forename: Nikolaos G
authors.initials: NG
authors.lastname: Dervisis
mesh_terms: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000235:genetics / Q000378:metabolism*; D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D014408:Biomarkers, Tumor / Q000032:analysis; D004283:Dog Diseases / Q000378:metabolism / Q000473:pathology* / Q000628:therapy; D004285:Dogs; D005260:Female; D007150:Immunohistochemistry / Q000662:veterinary; D008228:Lymphoma, Non-Hodgkin / Q000378:metabolism / Q000473:pathology / Q000628:therapy / Q000662:veterinary*; D008297:Male; D060787:Neoplasm Grading / Q000662:veterinary; D012074:Remission Induction; D016019:Survival Analysis; D016159:Tumor Suppressor Protein p53 / Q000235:genetics / Q000378:metabolism*
chemical_list: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D014408:Biomarkers, Tumor; D016159:Tumor Suppressor Protein p53